center orange

The live and archived webcast of the presentation can be accessed at
http://www. 26th Annual Health Care Conference in Boston on Tuesday, March 7,
2006 at 3:10 p. The company's product portfolio is
comprised of three approved products and multiple product and preclinical
product candidates . For additional
information, please visit http://www. BioMarin Pharmaceutical Inc. TNX-355 received Fast Track Status
from the U.tanox.

pharmacists find

Investigational product candidates
include Phenoptin (TM) (sapropterin dihydrochloride), a Phase 3 product
candidate for the treatment of phenylketonuria (PKU). and was approved for marketing in the United States in 2003 for adult and
adolescent patients with moderate-to-severe, confirmed allergic asthma.4211
ssievert@tanox.

disease conference

m. is a biopharmaceutical company engaged in the
discovery and development of drugs for the treatment of human viral and other
infectious diseases.com.
Orapred(R) is a registered trademark of Medicis Pediatrics, Inc.

Contact:
Steve Sievert
713.

aids immune

578.

nurses clinical

Tanox
is based in Houston, Texas and maintains a manufacturing facility in San
Diego, California.

conferences conditions

ET. A replay of the
presentation will be archived on the site for at least one week following the
presentation. and Vice
President of Finance Greg Guidroz will outline results for the first quarter,
provide an update on the company 's operations and lead a question-and-answer
session. The webcast will be accessible from the Tanox Web site at
http://www.
Tanox is a biotechnology company specializing in the discovery and
development of biotherapeutics based on monoclonal antibody technology.

pharmacists front

Idenix's current focus is on the treatment of infections
caused by hepatitis B virus, hepatitis C virus and human immunodeficiency
virus (HIV). Information on BioMarin's website is
not incorporated by reference into this press release.
The company develops innovative therapeutic agents for the treatment of
immune-mediated diseases, inflammation, infectious disease and cancer.

conferences clinical

, Idenix's chairman and chief executive officer , will present
a corporate overview at the upcoming SG Cowen 25th Annual Health Care
Conference on March 17, 2005 at 9:40 a.
Tanox President and Chief Executive Officer Nancy T.

disorders find

conference faq

m. Food and Drug Administration in 2003 and is currently in Phase 2
clinical testing.G.

update aids

, Idenix
Pharmaceuticals , Inc. ET at the The Boston Marriott Copley
Place, Boston, MA.

Contact:
Idenix Pharmaceuticals, Inc.

NOTE: Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.
Live audio of the conference call will be simultaneously webcast on the
Internet.

line deficiency

(Nasdaq: IDIX) announced today that Jean-Pierre
Sommadossi, Ph. Tanox's first-approved drug, Xolair(R) (omalizumab ), is the
first anti-immunoglobulin E (anti-IgE) antibody to be brought to market.

update line

Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838

(Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief
Executive Office of BioMarin, will present a company update at the
Cowen + Co.
415-506-6777 415-506-6701

physicians line

zhtml?ticker=IDIX+item_id=1031417
or under "Calendar of Events" in the Idenix Investor Center at
http://www.com.BMRN. Chang, Ph.

About Tanox, Inc.

california physicians

corporate-ir.com.m.com .

disorders immune

Idenix's headquarters are located in Cambridge, Massachusetts
and it has drug discovery operations in Montpellier , France and Cagliari,
Italy. Grass Susan Ferris
BioMarin Pharmaceutical Inc. HOUSTON, Tanox, Inc.com in the Investor Relations section.S.

update pharmacists

net/ireye/confLobby.BMRN. and Novartis Pharma
A.

conference line

The announcement will be made prior to market open, with a conference call
for the financial community to follow at 10 a.D.

physicians conditions

CAMBRIDGE, Mass.

About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions .com

hiv find

About Idenix:
Idenix Pharmaceuticals, Inc. Approved products include Naglazyme(TM) (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin, Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate
oral solution) for inflammatory conditions. and is
used under license.

Contacts:

Investors Media
Joshua A. (Nasdaq: TNOX)
will announce its 2005 first quarter financial results May 4, 2005.
Tanox's lead investigational therapy, TNX-355, is a humanized, anti-CD4
monoclonal antibody to treat HIV and AIDS.

california center

Interested parties may access a live audio webcast of the presentation via
the investor section of the BioMarin website, http://www.

Tanox to Report First Quarter 2005 Financial Results Host Conference Call for Investors May 4

, EDT. Additional corporate information is available at
http: //www.

form aids

Idenix Pharmaceuticals to Present at the SG Cowen 25th Annual Health Care Conference

NOVATO , Calif, BioMarin Pharmaceutical
Inc.

conferences aids

BioMarin to Present at Cowen + Co. 26th Annual Health Care Conference

tanox.
Xolair was developed in collaboration with Genentech, Inc.

find immune

idenix. The archived replay will be available on the Idenix
website for two weeks following the presentation.